PMC:7195088 / 10877-11169 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T48","span":{"begin":231,"end":248},"obj":"Chemical"},{"id":"T49","span":{"begin":238,"end":248},"obj":"Chemical"}],"attributes":[{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_23924"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"e is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modificat"}

{"project":"LitCovid-sentences","denotations":[{"id":"T72","span":{"begin":56,"end":261},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"e is no information on any possible effect on survival. In the absence of clinical studies, we suggest to preferentially administer also other immunosuppressive and/or immunomodulatory therapies (e.g. anakinra, Janus kinase family enzyme inhibitors) within RCT. This also applies to modificat"}